Table 2.

MAFLD and adverse outcomes.

Outcome	HR	95% CI	p value
Clinical event∗
Unadjusted	3.01	1.91–4.73	<0.001
Multivariate†	2.00	1.26–3.19	0.003
HCC/transplant/death
Unadjusted	3.04	1.85–4.98	<0.001
Multivariate†	1.93	1.17–3.21	0.011
Transplant/death
Unadjusted	2.82	1.56–5.09	<0.001
Multivariate†	1.80	0.98–3.29	0.058

Results were obtained with Cox proportional hazards analysis and given as HR with 95% CI.

HCC, hepatocellular carcinoma; HR, hazard ratio.

^∗Clinical event: decompensation, HCC, transplant, or death.

^†Adjusted for age, sex, HBeAg serostatus, advanced fibrosis, and antiviral treatment.